New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
March 27, 2015
16:12 EDTHNTHealth Net receives contract extension for TRICARE program
Subscribe for More Information
March 25, 2015
16:05 EDTMDTMedtronic highlights data on patients undergoing laparoscopic colon resections
Subscribe for More Information
10:00 EDTUNHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:38 EDTAET, CI, UNHPrice targets raised for Managed Care Organizations at UBS
UBS raised its price targets on the Managed Care Organizations in their coverage universe. The firm cites increased volumes, a lack of new legislation, the potential for industry consolidation, and limited exposure to international markets that face a weak macro economic backdrop. UBS raised its price target on Aetna (AET) to $128 from $120, Anthem (ANTM) to $175 from $163, Cigna (CI) to $149 from $140 and United Health (UNH) to $135 from $131. UBS has a Buy rating on all four stocks.
07:05 EDTUNHUnitedHealth initiated with a Buy at Mizuho
Subscribe for More Information
March 24, 2015
16:06 EDTBSXBoston Scientific announces first commercial procedures with Watchman Device
This week, three patients in the U.S. received the first implants of the Boston Scientific Watchman Left Atrial Appendage Closure, or LAAC, Device. The WATCHMAN Device offers a novel stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation, or AF, who are seeking an alternative to long-term warfarin therapy. The Watchman Device received FDA approval on Friday, March 13. The first Watchman Device procedures in the U.S. were performed by Shephal K. Doshi, M.D., director of Cardiac Electrophysiology and Pacing at Saint John's Health Center in Santa Monica, CA, and Saibal Kar, M.D., director of the Cardiovascular Intervention Center Research at Cedars-Sinai Hospital in Los Angeles, CA.
08:49 EDTHUMHumana price target raised to $193 from $167 at Oppenheimer
Oppenheimer increased its price target on Humana (HUM) to reflect the company's sale of Concentra to Select Medical (SEM) and Welsh Carson for $1.055B. The firm says that the deal is likely to be supportive of Humana's earnings growth over the longer term. It keeps an Outperform rating on the shares.
07:43 EDTHUMDaVita subpoenas have mixed outcomes, says William Blair
Subscribe for More Information
07:41 EDTHUMHumana received DOJ request for information on Medicare
Subscribe for More Information
06:12 EDTWCGWellCare says Chairman David Gallitano will not stand for re-election
Subscribe for More Information
March 23, 2015
16:19 EDTBSXBoston Scientific leads funding round for InterVene
Subscribe for More Information
12:17 EDTHUMOn The Fly: Midday Wrap
Subscribe for More Information
09:07 EDTHUMSelect Medical agrees to acquire Concentra through JV with Welsh Carson
Subscribe for More Information
09:04 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
Humana (HUM) has reached a definitive agreement to sell the stock of its wholly-owned subsidiary, Concentra, to MJ Acquisition Corporation, a joint venture between Select Medical Holdings Corporation (SEM), an operator of specialty hospitals and outpatient rehabilitation clinics in the U.S., and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund, for approximately $1.055B in cash, subject to customary adjustments. Humana acquired Concentra in December 2010. Subsequently, the assets of certain privately-operated Community Based Outpatient Clinics were transferred into Concentra. Additionally, Humana has divested certain Concentra non-core assets over the past four years. The decision to divest Concentra demonstrates the company’s commitment to its previously announced business portfolio review. Humana will continue performing its review of the alignment and return potential of businesses across the organization to ensure each supports the company’s integrated care delivery strategy and earns the appropriate return on invested capital. The Concentra transaction is anticipated to close during the second quarter of 2015 subject to Hart Scott Rodino regulatory clearance and customary closing conditions. Humana anticipates using the net proceeds from the transaction to advance its strategic growth priorities, to fund additional share repurchases under its existing $2 billion authorization and for general corporate purposes. Goldman, Sachs & Co. is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP is acting as legal advisor to Humana. Concentra reported revenues for the year ended December 31, 2014 were approximately $1B. Humana anticipates the Concentra divestiture will be slightly dilutive to 2015 EPS excluding any one-time gain expected upon the close of the transaction.
09:02 EDTHUMHumana reiterates FY15 EPS view $8.50-$9.00, concensus $8.87
Subscribe for More Information
09:02 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
March 20, 2015
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTBSXBoston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on March 27 at 11 am.
08:18 EDTCNC, HNT, UNH, WCG, HUM, CI, MOH, AETLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
06:44 EDTBSXBoston Scientific initiated with an Outperform at Raymond James
Subscribe for More Information
March 19, 2015
10:12 EDTHNTHealth Net to reaffirm FY15 EPS guidance 'at least' $2.70
Subscribe for More Information
10:02 EDTAETOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:20 EDTAETAetna upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space , a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm.
06:19 EDTAETAetna upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
March 18, 2015
12:46 EDTAETAetna, HackensackAlliance ACO announce collaboration
Subscribe for More Information
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:39 EDTBSX, STJ, MDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:13 EDTBSXBoston Scientific announces FDA, CE Mark approval of EMBLEM S-ICD system
Boston Scientific has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator, or S-ICD, system. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest, yet leaves the heart and vasculature untouched, minimizing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May and subsequent U.S. launch planned for the third quarter of 2015.
09:00 EDTAETAetna management to meet with JPMorgan
Subscribe for More Information
March 16, 2015
13:16 EDTMDT, STJ, BSXAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
10:56 EDTMOHMolina Healthcare management to meet with Sterne Agee
Subscribe for More Information
09:22 EDTBSXOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTHUMHumana announcse completion of $500M accelerated share repurchase program
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical data 'impressive,' says BMO Capital
Subscribe for More Information
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:25 EDTBSXBoston Scientific Watchman indication 'very favorable,' says Bernstein
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
12:47 EDTSTJSt. Jude Medical announces new data analysis from CHAMPION trial
St. Jude Medical announced a new data analysis from the CHAMPION trial showing that heart failure, HF, patients with reduced ejection fraction on optimal doses of guideline directed medical therapy, GDMT, managed by pulmonary artery, PA, pressure monitoring with the CardioMEMS HF System had a 57% reduction in mortality and a 43% reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care, SOC. These data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices.
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use